Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000195038 | SCV000249413 | likely benign | not specified | 2021-06-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002315519 | SCV000849179 | likely benign | Inborn genetic diseases | 2017-04-08 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV000765982 | SCV000897408 | uncertain significance | Cohen syndrome | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000765982 | SCV001098904 | likely benign | Cohen syndrome | 2024-12-24 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001706171 | SCV004158265 | likely benign | not provided | 2022-07-01 | criteria provided, single submitter | clinical testing | VPS13B: BP4, BP7 |
Natera, |
RCV000765982 | SCV001460389 | uncertain significance | Cohen syndrome | 2020-01-24 | no assertion criteria provided | clinical testing | |
Clinical Genetics, |
RCV001706171 | SCV001919582 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001706171 | SCV001970626 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Prevention |
RCV003917778 | SCV004736569 | likely benign | VPS13B-related disorder | 2023-10-25 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |